nach oben

Erschienen in:

01.02.2017 | ONCOLOGY IMAGING

Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up

verfasst von: Pietro Valerio Foti, Antonio Longo, Michele Reibaldi, Andrea Russo, Giuseppe Privitera, Corrado Spatola, Luigi Raffaele, Vincenzo Salamone, Renato Farina, Stefano Palmucci, Andrea Musumeci, Rosario Caltabiano, Marco Ragusa, Cesare Mariotti, Teresio Avitabile, Pietro Milone, Giovanni Carlo Ettorre

Erschienen in: La radiologia medica | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this prospective study was to investigate the proton-beam-induced changes in apparent diffusion coefficient (ADC) values of ocular melanoma treated with proton-beam therapy (PBT) in patients undergoing long-term magnetic resonance imaging (MRI) follow-up and to assess whether variations in ADC constitute a reliable biomarker for predicting and detecting the response of ocular melanoma to PBT.

Methods

Seventeen patients with ocular melanoma treated with PBT were enrolled. All patients underwent conventional MRI and diffusion-weighted imaging (DWI) at baseline and 1, 3, 6, and 18 months after the beginning of therapy. Tumor volumes and ADC values of ocular lesions were measured at each examination. Tumor volumes and mean ADC measurements of the five examination series were compared; correlation of ADC values and tumor regression was estimated.

Results

Mean ADC values of ocular melanomas significantly increased already 1 month after therapy whereas tumor volume significantly decreased only 6 months after therapy. Pretreatment ADC value of ocular melanomas and early change in ADC value 1 month after therapy significantly correlated with tumor regression.

Conclusions

In ocular melanoma treated with PBT, ADC variations precede volume changes. Both pretreatment ADC and early change in ADC value may predict treatment response, thus expanding the role of DWI from diagnostic to prognostic.

Dieckmann K, Georg D, Zehetmayer M et al (2003) Linac based stereotactic radiotherapy of uveal melanomas: 4 years clinical experience. Radiother Oncol 67:199–203CrossRefPubMed

McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW (2005) Incidence of noncutaneous melanomas in the US. Cancer 103:1000–1007CrossRefPubMed

Damato B, Kacperek A, Errington D et al (2013) Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 27(3):151–157CrossRefPubMedPubMedCentral

Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Jagannathan JP, Ramaiya NH (2015) Extracutaneous melanomas: a primer for the radiologist. Insights Imaging 6(6):707–717. doi:10.1007/s13244-015-0427-8 CrossRefPubMedPubMedCentral

Purohit BS, Vargas MI, Ailianou A, Merlini L, Poletti PA, Platon A, Delattre BM, Rager O, Burkhardt K, Becker M (2016) Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging. Insights Imaging 7(1):43–68. doi:10.1007/s13244-015-0443-8 CrossRefPubMed

Groenewald C, Konstantinidis L, Damato B (2013) Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond) 27(2):163–171. doi:10.1038/eye.2012.249 CrossRef

Marnitz S, Cordini D, Bendl R, Lemke AJ, Heufelder J, Simiantonakis I, Kluge H, Bechrakis NE, Foerster MH, Hinkelbein W (2006) Proton therapy of uveal melanomas: intercomparison of MRI-based and conventional treatment planning. Strahlenther Onkol 182(7):395–399CrossRefPubMed

Verma V, Mehta MP (2016) Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol) 28(8):e17–e27. doi:10.1016/j.clon.2016.01.034 CrossRef

Kamrava M, Sepahdari AR, Leu K, Wang PC, Roberts K, Demanes DJ, McCannel T, Ellingson BM (2015) Quantitative multiparametric MRI in uveal melanoma: increased tumor permeability may predict monosomy 3. Neuroradiology 57(8):833–840. doi:10.1007/s00234-015-1546-0 CrossRefPubMed

10.

Maschi C, Thariat J, Herault J, Caujolle JP (2016) Tumour response in uveal melanomas treated with proton beam therapy. Clin Oncol (R Coll Radiol) 28(3):198–203. doi:10.1016/j.clon.2015.08.007 CrossRef

11.

Russo A, Mariotti C, Longo A et al (2015) Diffusion-weighted magnetic resonance imaging and ultrasound evaluation of choroidal melanomas after proton-beam therapy. Radiol Med 120(7):634–640. doi:10.1007/s11547-015-0509-1 CrossRefPubMed

12.

Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32(1):2–16. doi:10.1002/jmri.22167 CrossRefPubMedPubMedCentral

13.

Kim S, Loevner L, Quon H et al (2009) Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 15:986–994CrossRefPubMedPubMedCentral

14.

Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394CrossRefPubMedPubMedCentral

15.

Vandecaveye V, Dirix P, De Keyzer F et al (2010) Predictive value of diffusion weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 20:1703–1714CrossRefPubMed

16.

Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21(6):1094–1100CrossRefPubMed

17.

The Collaborative Ocular Melanoma Study Group (1990) Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report No. 1. Arch Ophthalmol 108:1268–1273CrossRef

18.

Foti PV, Farina R, Coronella M, Palmucci S, Montana A, Sigona A, Reibaldi M, Longo A, Russo A, Avitabile T, Caltabiano R, Puzzo L, Ragusa M, Mariotti C, Milone P, Ettorre GC (2015) Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. Radiol Med 120(6):526–535. doi:10.1007/s11547-014-0488-7 CrossRefPubMed

19.

Cirrone GAP, Cuttone G, Lojacono PA, Lo Nigro S, Mongelli V, Patti IV, Privitera G, Raffaele L, Rifuggiato D, Sabini MG, Salamone V, Spatola C, Valastro LM (2004) A 62 MeV proton beam for the treatment of ocular melanoma at Laboratori Nazionali del Sud-INFN. IEEE Trans Nucl Sci 51:860–865. doi:10.1109/TNS.2004.829535 CrossRef

20.

Goitein M, Miller T (1983) Planning proton therapy of the eye. Med Phys 10(3):275–283CrossRefPubMed

21.

de Graaf P, Pouwels PJ, Rodjan F et al (2012) Single-shot turbo spin-echo diffusion-weighted imaging for retinoblastoma: initial experience. AJNR Am J Neuroradiol 33:110–118CrossRefPubMed

22.

Erb-Eigner K, Willerding G, Taupitz M et al (2013) Diffusion-weighted imaging of ocular melanoma. Invest Radiol 48(10):702–707CrossRefPubMed

23.

Sepahdari AR, Kapur R, Aakalu VK et al (2012) Diffusion-weighted imaging of malignant ocular masses: initial results and directions for further study. AJNR Am J Neuroradiol 33:314–319CrossRefPubMed

24.

Tseng VL, Coleman AL, Zhang Z-F, McCannel TA (2016) Complications from plaque versus proton beam therapy for choroidal melanoma: a qualitative systematic review. J Cancer Ther 7:169–185 (special issue-melanoma) CrossRef

25.

Politi LS, Forghani R, Godi C et al (2010) Ocular adnexal lymphoma: diffusion weighted MR imaging for differential diagnosis and therapeutic monitoring. Radiology 256:565–574CrossRefPubMed

26.

Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed

27.

Dzik-Jurasz A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307–308CrossRefPubMed

28.

Liu Y, Bai R, Sun H et al (2009) Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 64:1067–1074CrossRefPubMed

29.

Papaevangelou E, Almeida GS, Jamin Y, Robinson SP, deSouza NM. (2015) Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. Br J Cancer 28;112(9):1471–1479. doi:10.1038/bjc.2015.134

30.

Mafee MF, Rapoport M, Karimi A, Ansari SA, Shah J (2005) Orbital and ocular imaging using 3- and 1.5-T MR imaging systems. Neuroimaging Clin N Am 15(1):1–21CrossRefPubMed

31.

Razek AA, Elkhamary S, Mousa A (2011) Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging. Neuroradiology 53(7):517–522. doi:10.1007/s00234-011-0838-2 CrossRefPubMed

32.

Schouten CS, de Bree R, van der Putten L, Noij DP, Hoekstra OS, Comans EF, Witte BI, Doornaert PA, Leemans CR, Castelijns JA (2014) Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer. Quant Imaging Med Surg. 4(4):239–250. doi:10.3978/j.issn.2223-4292.2014.07.15 PubMedPubMedCentral

Titel: Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up
verfasst von: Pietro Valerio Foti
Antonio Longo
Michele Reibaldi
Andrea Russo
Giuseppe Privitera
Corrado Spatola
Luigi Raffaele
Vincenzo Salamone
Renato Farina
Stefano Palmucci
Andrea Musumeci
Rosario Caltabiano
Marco Ragusa
Cesare Mariotti
Teresio Avitabile
Pietro Milone
Giovanni Carlo Ettorre
Publikationsdatum: 01.02.2017
Verlag: Springer Milan
Erschienen in: La radiologia medica / Ausgabe 2/2017
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-016-0697-3

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up